Chen Xue-Jun - Incyte Res Inst, Incyte Corp

基本信息

浏览量：93

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 77 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics when Administered Orally in Healthy Participants

Yan-Ou Yang,Xiaohua Gong,Phillip Wang, Xiang Liu, Jay Getsy, Jennifer Sheng,Swamy Yeleswaram,Xuejun Chen,Kevin Rockich

Clinical pharmacology in drug development (2025)

引用0浏览0WOS引用

Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease

Yan-Ou Yang, Alina Volkova,Victor Sokolov, Xing Liu, Cristina Leon,Yuri Kosinsky, Jennifer Sheng,Xuejun Chen

Clinical pharmacology and therapeutics (2025)

引用0浏览0WOS引用

A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis

Linda Stein Gold,Robert Bissonnette,Seth Forman,Andrea Zaenglein,YuTzu Kuo,Brett Angel,Xuejun Chen,Howard Kallender,Amy S. Paller

American Journal of Clinical Dermatologypp.1-15, (2025)

引用0浏览0WOS引用

Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years with Atopic Dermatitis: Results from TRuE-AD3, a Phase 3, Randomized Double-Blind Study

Lawrence F Eichenfield, Linda F Stein Gold, Eric L Simpson,Andrea L Zaenglein,April W Armstrong,Megha M Tollefson,Weily Soong,Lara Wine Lee, Alim R Devani,Seth B Forman, Dareen D Siri,Howard Kallender, Brett Angel, Qian Li,Xuejun Chen,Amy S Paller

Journal of the American Academy of Dermatology (2025)

引用0浏览0WOS引用

PD‐1 Inhibition with Retifanlimab And/or Arginase Inhibition with INCB001158 in Japanese Patients with Solid Tumors: A Phase I Study

Yasutoshi Kuboki,Takafumi Koyama,Nobuaki Matsubara,Yoichi Naito,Shunsuke Kondo,Kenichi Harano,Kan Yonemori,Kiyotaka Yoh,Yuan Gu,Tetsuya Mita,Xuejun Chen,Eiji Ueda,Noboru Yamamoto,Toshihiko Doi,Toshio Shimizu

CANCER MEDICINE（2024）

引用0浏览0WOS引用

Pharmacokinetics of Zilurgisertib with and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults

Yan-ou Yang,Xiaohua Gong, Jay Getsy,Phillip Wang, Xiang Liu,Jennifer Sheng,Xuejun Chen,Kevin Rockich

European journal of drug metabolism and pharmacokineticsno. 1 (2024): 65-80

引用0浏览0WOS引用

Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients with Solid Tumors or Chronic Graft-Versus-Host Disease

Yan-ou Yang,Victor Sokolov, Alina Volkova, Xing Liu, Cristina Leon,Yuri Kosinsky,Breann Barker, Xuecheng Zhang,Peter Ordentlich,Jennifer Sheng,Xuejun Chen

CLINICAL PHARMACOLOGY & THERAPEUTICS (2024)

引用0浏览0WOS引用

54168 Maximum-Use Trials of Ruxolitinib Cream in Adults, Adolescents, and Children Aged 2 to <12 Years with Atopic Dermatitis: Consistency of Safety, Pharmacokinetics, and Efficacy

Robert Bissonnette,Wynnis L. Tom,Daniel Sturm,Brett Angel,Xuejun Chen,Yutzu Kuo,Mark S. Lee

Journal of the American Academy of Dermatologyno. 3 (2024): AB254

引用0浏览0引用

First-in-human Phase 1 Study of the Arginase Inhibitor INCB001158 Alone or Combined with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumours

Aung Naing,Kyriakos P Papadopoulos,Michael J Pishvaian,Osama Rahma,Glenn J Hanna,Elena Garralda,Omar Saavedra,Sven Gogov,Howard Kallender,LuLu Cheng,Michael Smith,Xuejun Chen, Emil Kuriakose,Todd Bauer

BMJ oncologyno. 1 (2024): e000249-e000249

引用1浏览0WOS引用

Exposure-Response Relationships for Axatilimab, a Humanized Monoclonal Antibody Targeting CSF-1R, in Patients with Chronic Graft-Versus-Host Disease

Yan-ou Yang, Alina Volkova,Victor Sokolov, Xing Liu, Cristina Leon,Yuri Kosinsky,Jennifer Sheng,Xuejun Chen

Bloodno. Supplement 1 (2024): 2140-2140

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn